← Back to Clinical Trials
Recruiting Phase 2 NCT04813705

18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma

Trial Parameters

Condition Nasopharyngeal Carcinoma
Sponsor Taizhou Hospital
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 93
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2022-01-01
Completion 2024-06-30
Interventions
Reduced doseConventional doseChemotherapy

Brief Summary

The purpose of this study is to explore whether 18F-FDG PET/CT guided reduced-dose radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (NPC) patients.

Eligibility Criteria

Inclusion Criteria: 1. Pathology confirmed nasopharyngeal squamous cell carcinoma. 2. Stage I-IVA(8thAJCC/UICC staging system). 3. Aged 18-80 years. 4. KPS≥70. 5. Have measurable lesions on 18F-FDG PET/CT before treatment. 6. HGB≥90 g/L,ANC≥1.5×109 /L,PLT≥80×109 /L. 7. ALT,AST\<2.5 fold of ULN;TBIL\<2.0×ULN. 8. CCR≥60ml/min or Cr\<1.5×ULN. 9. Signed informed consent. 10. Have follow up condition. Exclusion Criteria: 1. Past malignancies history (except for stage I non-melanoma skin cancer or cervical carcinoma in situ). 2. Age \<18 or \>80years. 3. Pregnancy or lactation. 4. History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume). 5. Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes. 6. With sever infection and internal disease. 7. Major organ dysfunction, such as decompensated cardiopulmonary, kidney, liver failure, cannot tolerate surgical treatment.

Related Trials